References
- Durham W. F., Hayes WJ. Organic phosphorus poisoning and its therapy. Arch Environ Health 1962; 5: 21–47
- Farrar H. C., Wells T. G., Kearns GL. Use of continuous infusion of pralidoxime for treatment of organophos-phate poisoning in children. J Pediatr 1990; 116: 658–661
- Shiloff J. D., Clement JG. Comparison of serum concentrations of the acetylcholinesterase oxime reactivators HI-6, obidoxime, and PAM to efficacy against sarin (isopropyl methylphosplonofluoridate) poisoning in rats. Toxicol Appl Pharmacol 1987; 89: 279–280
- Rowland M., Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. Lea & Febiger, Philadelphia 1989; 131–147
- Ellenhorn MJ. Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Elsevier, New York 1996; 1614–1631
- Haddad L. M., Shannon M., Winchester JF. Clinical Management of Poisoning and Drug Overdose. WB Saunders Company, Philadelphia 1998; 836–840
- Poisondex. Micromedex, Inc., Denver, CO
- Namba T., Nolte C. T., Jackrel J., Grob D. Poisoning due to organophosphate insecticides. Acute and chronic manifestations. Am J Med, 50(171)475–492
- Hayes W. J., Laws ER. Handbook of Pesticide Toxicology. Academic Press, San Diego 1991; 388–398
- Willems J. L., Langenber J. P., Verstraete A. G. Plasma concentrations of pralidoxime methylsulphate in organophosphorus poisoned patients. Arch Toxicol 1992; 66: 260–263
- Willems J. L., De Bisschop H. C., Verstraete A. G. Cholinesterase reactivation in organophosphorus poisoned patients depends on the plasma concentrations of the oxime pralidoxime methylsulphate and of the organophosphate. Arch Toxicol 1993; 167: 79–84
- Johnson M. K., Vale J. A., Marrs T. C., Meredith TJ. Pralidoxime for organophosphorus poisoning. Lancet 1992; 340: 64
- Tush G. M., Anstead MI. Pralidoxime continuous infusion in the treatment of organophosphate poisoning. Ann Pharmacother 1997; 31: 441–444
- Dawson A., Buckley N., Whyte I. What target pralidoxime concentration. J Toxicol Clin Toxicol 1997; 35: 227–228
- Thompson DF. Pralidoxime chloride continuous infusions. Ann Emerg Med 1987; 16: 831–832
- Sundwall A. Minimum concentrations of N-methyl-pyridium-2-aldoxime methane sulfonate (P2S) which reverse neuromuscular block. Biochem Pharmacol 1961; 18: 413–417
- Crook J. L., Goodman A. D., Colburn J. L. Adjunctive value of oral prophylaxis with the oximes 2-PAM lactate and 2-PAM methanesulfonate to therapeutic administration of atropine in dogs poisoned by inhaled sarin vapor. J Pharmacol Exp Ther 1962; 136: 397–399
- Zvirblis P., Kondritzer AA. Prophylaxis against sarin poisoning in the rat by oral administration of pralidoxime chloride. J Pharmacol Exp Ther 1967; 157: 432–434
- Thompson D. F., Thompson G. D., Greenwood R., Trammel HL. Therapeutic dosing of pralidoxime chloride. Drug Intell Clin Pharm 1987; 21: 590–593
- Calesnick B., Christensen J. A., Richter M. Human toxicity of various oximes. Arch Environ Health 1967; 15: 599–608
- Sidell F. R., Graff W. A., Kaminskis A. Toxogonin and pralidoxime: Kinetic comparison after intravenous administration to man. J Pharm Sci 1972; 61: 1765–1769
- Swartz R. D., Sidell FR. Renal tubular secretion of pralidoxime in man. Proc Soc Exp Biol Med 1972; 146: 419–424
- Medicis J. J., Stork G. M., Howland M. A., Hoffman R. S., Goldfrank LR. Pharmacokinetics following a loading plus a continuous infusion of pralidoxime compared with the traditional short infusion regimen in human volunteers. J Toxicol Clin Toxicol 1996; 34: 289–295
- Kearns G. L., Reed MD. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinetics 1989; 17: 29–67, supp. 1